Supernus Pharmaceuticals, Inc. (SUPN)
| Previous Close | 33.84 |
| Open | 34.09 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 33.71 - 34.51 |
| 52 Week Range | 21.99 - 35.44 |
| Volume | |
| Avg. Volume | 425,115 |
| Market Cap | 1.902B |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | 383.50 |
| EPS (TTM) | 0.09 |
| Earnings Date | Nov 06, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.25 |
GlobeNewswireSupernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression Company to host webcast today at 4:30 p.m. ET to discuss the topline data Topline results from Phase 2b randomized double-blind placebo-controlled study of SPN-820 in adults with treatment-resistant depression expected first-half 2025 ROCKVILLE, Md., Oct. 17, 2024 (
- GlobeNewswire
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, October 17, 2024, at 4:30 p.m. ET to review data from the open-label Phase 2a study of SPN-820 for the treatment of major depressive disorder. A live webcast with presentation sl
GuruFocus.comSupernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Supernus Pharmaceuticals Inc (SUPN) reports a 32% revenue increase, driven by Qelbree and Gocovri, while advancing its product pipeline and raising full-year guidance.
